Antonella Chadha Santuccione, MD, Co-founder and CEO of the Women’s Brain Project and Chief Medical Officer at Altoida Inc., shares an overview of sex and gender differences in Alzheimer’s disease (AD) and their implications for clinical research and patient care. As part of their dedication to precision medicine and care, the Women’s Brain Project (WBP) study how sex and gender influences the prevalence, incidence, disease characteristics, diagnosis, and treatment response in AD. Research reveals that almost 70% of AD patients are female, women experience a faster progression of the disease, and also exhibit a higher prevalence of neurodegenerative changes, such as hippocampal atrophy, compared to men. Biomarkers like tau also have a more prominent role in the female brain, even at the same stage of the disease. Additionally, inherent biases in the medical field can lead to women’s concerns being dismissed, delaying accurate diagnosis and appropriate intervention. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
